Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell division cycle protein 27 homolog (CDC27) is an essential subunit of the anaphase-promoting complex/cyclosome (APC/C), a large E3 ubiquitin ligase that regulates cell cycle progression by targeting key cell cycle proteins such as cyclin B and securin for proteasomal degradation[3][4][5][1]. CDC27 contains tetratricopeptide repeat (TPR) domains, enabling interactions with mitotic checkpoint proteins (such as Mad2, BubR1, p55CDC) and recruitment of coactivators CDC20 and CDH1, both of which are crucial for proper timing of mitosis and G1 phase transition[2][3][5][6][1]. Dysregulation of CDC27 or APC/C complex function contributes to genomic instability and is associated with the development of cancer and related cell cycle disorders[6][5]. No approved therapeutics directly target CDC27/APC3; however, the APC/C complex is an emerging cancer drug target[6].
Inhibition or modulation of APC/C complex activity (notably through targeting its E3 ligase function) Modulation of substrate ubiquitination and degradation (indirect, as APC/C is not yet a direct drug target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell division cycle protein 27 homolog (CDC27).